Explore All Access
Check if your research matches the topics covered in CORE EVIDENCE?
- Degree of match
- Common matching concepts
- Additional journal recommendations
CORE EVIDENCE : Impact Factor & More
eISSN: 1555-175XpISSN: 1555-1741
Share this on:
Check your submission readiness
Find out how your manuscript stacks up against 24 technical compliance and 6 language quality checks.
Aims and Scope
Core Evidence is a peer-reviewed healthcare journal covering research on drug development. The journal was established in 2005 and is published by Dove Medical Press.
CORE EVIDENCE Journal Specifications
Indexed in the following public directories
Web of Science
| Overview | |
| Publisher | DOVE MEDICAL PRESS LTD |
| Language | English |
| Frequency | Continuous publication |
| General Details |
View less
Planning to publish in CORE EVIDENCE ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in CORE EVIDENCE
Riociguat in the Treatment of Chronic Thromboembolic Pulmonary Hypertension: An Evidence-Based Review of Its Place in Therapy.
- 1 Aug 2020
- Core Evidence
Management of Chemotherapy-Induced Nausea and Vomiting (CINV): A Short Review on the Role of Netupitant-Palonosetron (NEPA).
- 1 Jul 2020
- Core Evidence
Vedolizumab in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Safety, Efficacy, and Place of Therapy.
- 1 Apr 2020
- Core Evidence
Apixaban: An Update of the Evidence for Its Place in the Prevention of Stroke in Patients with Atrial Fibrillation.
- 1 Jan 2020
- Core Evidence
Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapy.
- 1 Oct 2019
- Core Evidence
Anabolics in the management of glucocorticoid-induced osteoporosis: an evidence-based review of long-term safety, efficacy and place in therapy.
- 1 Aug 2019
- Core Evidence
Riociguat in the Treatment of Chronic Thromboembolic Pulmonary Hypertension: An Evidence-Based Review of Its Place in Therapy.
- 1 Aug 2020
- Core Evidence
Management of Chemotherapy-Induced Nausea and Vomiting (CINV): A Short Review on the Role of Netupitant-Palonosetron (NEPA).
- 1 Jul 2020
- Core Evidence
Vedolizumab in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Safety, Efficacy, and Place of Therapy.
- 1 Apr 2020
- Core Evidence
Apixaban: An Update of the Evidence for Its Place in the Prevention of Stroke in Patients with Atrial Fibrillation.
- 1 Jan 2020
- Core Evidence
Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapy.
- 1 Oct 2019
- Core Evidence
Anabolics in the management of glucocorticoid-induced osteoporosis: an evidence-based review of long-term safety, efficacy and place in therapy.
- 1 Aug 2019
- Core Evidence
FAQs on CORE EVIDENCE
How long has CORE EVIDENCE been actively publishing? 
CORE EVIDENCE has been in operation since 2005 till date.
What is the publishing frequency of CORE EVIDENCE?
CORE EVIDENCE published with a Continuous publication frequency.
How many articles did CORE EVIDENCE publish last year?
In 2023, CORE EVIDENCE publsihed undefined articles.
What is the eISSN & pISSN for CORE EVIDENCE?
For CORE EVIDENCE, eISSN is 1555-175X and pISSN is 1555-1741.
Who is the publisher of CORE EVIDENCE?
DOVE MEDICAL PRESS LTD is the publisher of CORE EVIDENCE.
